drugset / Trial / NCT01858961
Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this trial is to evaluate efficacy and safety of treatment with 600 mg of BID BI 207127 in combination with 120 mg QD Faldaprevir and RBV compared to a Telaprevir-based regimen along with PegIFN and RBV in chronically infected HCV GT1 treatment naïve patients, including patients with compensated cirrhosis.
Timeline
- Start
- 2013-05
- Primary completion
- 2016-07
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deleobuvir | Small molecule | 600 mg | — |
| Subject | Faldaprevir | Small molecule | 120 mg | — |
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | — | — |
| Subject | Telaprevir | Small molecule | — | — |
| Background | Ribavirin | Small molecule | — | — |